Allergy Therapeutics (AGY) — Cash Flow Quality Index
Allergy Therapeutics (AGY) has a Cash Flow Quality Index of 0.56x as of December 2021. Operating cash flow of GBX3.71 Million is below net income of GBX6.67 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Allergy Therapeutics cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Allergy Therapeutics Cash Flow Quality Index (2003–2021)
Historical Cash Flow Quality Index for Allergy Therapeutics across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Allergy Therapeutics (AGY) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Allergy Therapeutics (2003–2021)
Year-by-year earnings quality comparison for Allergy Therapeutics. For live market cap and the full company financial profile, see market value of Allergy Therapeutics.
| Year | Quality Index | Operating CF (GBX) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 2.95x | GBX8.52 Million | GBX2.89 Million | ▲ +69.7% |
| 2020 | 1.74x | GBX12.28 Million | GBX7.06 Million | ▲ +7.7% |
| 2019 | 1.62x | GBX5.60 Million | GBX3.47 Million | ▼ -94.4% |
| 2015 | 28.92x | GBX3.12 Million | GBX108.00K | ▲ +886.1% |
| 2014 | 2.93x | GBX2.17 Million | GBX741.00K | ▼ -47.9% |
| 2013 | 5.63x | GBX2.43 Million | GBX432.00K | ▲ +25.1% |
| 2012 | 4.50x | GBX2.88 Million | GBX640.00K | ▲ +125.5% |
| 2011 | -17.63x | GBX-2.03 Million | GBX115.00K | ▼ -1607.8% |
| 2010 | 1.17x | GBX1.70 Million | GBX1.46 Million | ▼ -4.6% |
| 2004 | 1.22x | GBX1.91 Million | GBX1.56 Million | ▼ -21.7% |
| 2003 | 1.56x | GBX2.10 Million | GBX1.34 Million | — |